Aktienanalyse zu Unicycive Therapeutics Inc (UNCY)

KI-Analyse of Unicycive Therapeutics Inc (UNCY)

Halten

Unicycive Therapeutics Inc is currently not a strong buy due to its recent performance and technical indicators. The current price is $3.49, which is significantly below its 52-week high of $8.74, indicating a potential for recovery but also substantial risk. The RSI is at 32.171, suggesting the stock is oversold, but the recent 5-day change is -2.51%, reflecting continued downward pressure. The forward P/E ratio is 2.0661, which could indicate potential value, but the company has a negative net income and gross profit in recent quarters, with a net income of -21,525,000 USD in Q4 2024 and -6,447,000 USD in Q2 2025. The main risk is the ongoing FDA issues, as highlighted by the recent news of executives being sued for failing to ensure compliance, which could further impact stock performance.

Bewertungskennzahlen

Das aktuelle erwartete KGV von Unicycive Therapeutics Inc (UNCY) beträgt 1.99, verglichen mit dem 5-Jahres-Durchschnitt von 0.45.

Erwartetes KGV

Fair bewertet

5J-Durchschnitt P/E

0.45

Aktuelles P/E

1.99

Überbewertet

7.03

Unterbewertet

-6.13

Erwartetes EV/EBITDA

Fair bewertet

5J-Durchschnitt EV/EBITDA

-6545.04

Aktuelles EV/EBITDA

0.00

Überbewertet

23017.88

Unterbewertet

-36107.96

Erwartetes KUV

Fair bewertet

5J-Durchschnitt P/S

4.06

Aktuelles P/S

0.74

Überbewertet

15.58

Unterbewertet

-7.46

Alphio-AI-Kursszenarien für UNCY

Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.

B

Bullisch

Bullisch · 25%UNCY

$5.26

Szenariopreis

B

Basis

Basis · 50%UNCY

$4.33

Szenariopreis

B

Bärisch

Bärisch · 25%UNCY

$3.97

Szenariopreis

Whales, die UNCY halten

L

Logos Global Management, L.P.

+ HältUNCY

+20.59%

3-Monats-Rendite

UNCY FAQ – beantwortet von Alphio AI

Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Unicycive Therapeutics Inc is currently not a strong buy due to its recent performance and technical indicators. The current price is $3.49, which is significantly below its 52-week high of $8.74, indicating a potential for recovery but also substantial risk. The RSI is at 32.171, suggesting the stock is oversold, but the recent 5-day change is -2.51%, reflecting continued downward pressure. The forward P/E ratio is 2.0661, which could indicate potential value, but the company has a negative net income and gross profit in recent quarters, with a net income of -21,525,000 USD in Q4 2024 and -6,447,000 USD in Q2 2025. The main risk is the ongoing FDA issues, as highlighted by the recent news of executives being sued for failing to ensure compliance, which could further impact stock performance.